SBFM 📈 Sunshine Biopharma - Overview
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US8677814035
SBFM: Cancer, Antiviral, Generic, Supplements, Antibiotic, Anti-Inflammatory
Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine Biopharma, Inc. is based in Fort Lauderdale, Florida. Web URL: https://sunshinebiopharma.com
Additional Sources for SBFM Stock
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
SBFM Stock Overview
Market Cap in USD | 6m |
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |
GiC Sub-Industry | Biotechnology |
IPO / Inception | 2009-10-30 |
SBFM Stock Ratings
Growth 5y | -91.4% |
Fundamental | -28.5% |
Dividend | - |
Rel. Strength Industry | -7934 |
Analysts | 5/5 |
Fair Price Momentum | 1.61 USD |
Fair Price DCF | - |
SBFM Dividends
No Dividends PaidSBFM Growth Ratios
Growth Correlation 3m | 4.1% |
Growth Correlation 12m | -92.3% |
Growth Correlation 5y | -75.2% |
CAGR 5y | -73.76% |
CAGR/Mean DD 5y | -0.92 |
Sharpe Ratio 12m | -1.57 |
Alpha | -117.76 |
Beta | 0.67 |
Volatility | 186.96% |
Current Volume | 126k |
Average Volume 20d | 169.6k |
What is the price of SBFM stocks?
As of January 10, 2025, the stock is trading at USD 2.97 with a total of 125,950 shares traded.
Over the past week, the price has changed by -5.11%, over one month by -0.34%, over three months by -1.00% and over the past year by -99.42%.
As of January 10, 2025, the stock is trading at USD 2.97 with a total of 125,950 shares traded.
Over the past week, the price has changed by -5.11%, over one month by -0.34%, over three months by -1.00% and over the past year by -99.42%.
Is Sunshine Biopharma a good stock to buy?
Probably not. Based on ValueRay Fundamental Analyses, Sunshine Biopharma (NASDAQ:SBFM) is currently (January 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -28.54 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of SBFM as of January 2025 is 1.61. This means that SBFM is currently overvalued and has a potential downside of -45.79%.
Probably not. Based on ValueRay Fundamental Analyses, Sunshine Biopharma (NASDAQ:SBFM) is currently (January 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -28.54 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of SBFM as of January 2025 is 1.61. This means that SBFM is currently overvalued and has a potential downside of -45.79%.
Is SBFM a buy, sell or hold?
Sunshine Biopharma has received a consensus analysts rating of 5.00. Therefor, it is recommend to buy SBFM.
Sunshine Biopharma has received a consensus analysts rating of 5.00. Therefor, it is recommend to buy SBFM.
- Strong Buy: 1
- Buy: 0
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecast for SBFM stock price target?
According to ValueRays Forecast Model, SBFM Sunshine Biopharma will be worth about 1.8 in January 2026. The stock is currently trading at 2.97. This means that the stock has a potential downside of -40.4%.
According to ValueRays Forecast Model, SBFM Sunshine Biopharma will be worth about 1.8 in January 2026. The stock is currently trading at 2.97. This means that the stock has a potential downside of -40.4%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 300 | 10001% |
Analysts Target Price | 3 | 1% |
ValueRay Target Price | 1.8 | -40.4% |